CAJ | 학술논문

为克服血源免疫球蛋白制品的不足,开发了抗甲肝病毒基因工程单克隆抗体anti-HAV IgG.用无血清培养基培养rCHO工程细胞株,上清液经过rProtein A SFF亲和层析→脱盐→离子交换层析→超滤换液纯化后,所得anti-HAV IgG纯度达99%以上,比活性约100IU/mg,anti-HAV IgG活性回收率40%.所纯化的anti-HAV IgG分子量150kD,等电点8.4～9.3.免疫印迹实验证实anti-HAV IgG为人源全抗体分子.亲和层析介质rProtein A SFF确实存在亲和配基脱落问题,但通过后续纯化步骤可有效除去.在亲和层析过程中加入高盐清洗步骤,可有效降低宿主DNA残留量水平.对样品中自由巯基含量进行了测定,认为非还原电泳图谱中低分子量条带是由于抗体分子内存在自由巯基引起.用该工艺制备的anti-HAV IgG各项纯度检测指标均达到我国对基因工程产品的质量要求.
위극복혈원면역구단백제품적불족,개발료항갑간병독기인공정단극륭항체anti-HAV IgG.용무혈청배양기배양rCHO공정세포주,상청액경과rProtein A SFF친화층석→탈염→리자교환층석→초려환액순화후,소득anti-HAV IgG순도체99%이상,비활성약100IU/mg,anti-HAV IgG활성회수솔40%.소순화적anti-HAV IgG분자량150kD,등전점8.4～9.3.면역인적실험증실anti-HAV IgG위인원전항체분자.친화층석개질rProtein A SFF학실존재친화배기탈락문제,단통과후속순화보취가유효제거.재친화층석과정중가입고염청세보취,가유효강저숙주DNA잔류량수평.대양품중자유구기함량진행료측정,인위비환원전영도보중저분자량조대시유우항체분자내존재자유구기인기.용해공예제비적anti-HAV IgG각항순도검측지표균체도아국대기인공정산품적질량요구.
In order to obviate the drawbacks of plasma immunoglobulins, the whole molecular recombinant human anti-HAV(hepatitis A virus)monoclonal antibody (anti-HAV IgG) produced and secreted by rCHO cells was purified and its physicochemical properties were extensively characterized. The rCHO cells were cultured in serum-free medium and the supernatants were collected. The recombinant human IgG molecules were sequentially purified by ultrafiltration, rProtein A Sepharose Fast Flow affinity chromatography, ion exchange chromatography and diafiltration. In affinity chromatography, prior to the target protein elution, an intermediate high salt wash step was inserted, different pH and salt concentrations were evaluated for the capacity of removing host cell DNA. The yield of the downstream purification process was approximately 40%. The purity of anti-HAV IgG thus generated was assayed with SEC-HPLC method, integration result showed that the monomeric IgG content was more than 99%. Western-blot was carried out with AP-antiHuman IgG (Fab specific) and AP-antiHuman IgG (Fc specific) respectively, the blot result demonstrated that the anti-HAV IgG is human antibody with Fab and Fc structure. The specific anti-HAV activity determined by ELISA was 100 IU/mg, with anti-HAV immunoglobulin as the working standard reference. Ligand leakage in the eluate of the affinity column was approximately 32 ng/mg IgG, while after further purification steps, it was decreased to less than 2 ng/mg IgG. Residual host cell DNA was monitored with solid dot blot assay, DNA can be removed effectively with intermediate high salt wash step in the affinity chromatography. Free sulfhydryl content of anti-HAV IgG was assayed with fluorescent spectrophotometer, the low molecular weight bands appeared in non-reducing SDS-PAGE may be caused by the presence of free sulfhydryl. The endotoxin content was less than 1EU/mg examined by standard LAL test procedures. Anti-HAV IgG prepared with this process is able to fulfill the regulatory requirements of State Food and Drug Administration for recombinant products.